|
Oct 9
|
180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector
|
|
Oct 3
|
180 Life Sciences Corp. - Corporate Updates
|
|
Jul 30
|
180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake
|
|
Jul 23
|
180 Life Sciences Granted an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
|
|
Mar 14
|
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
|
|
Feb 26
|
180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
|
|
Dec 4
|
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
|
|
Nov 28
|
180 Life Sciences Announces Review of Strategic Alternatives
|
|
Aug 10
|
180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
|
|
Aug 7
|
180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
|